Boenning & Scattergood’s Jazz Pharmaceuticals JAZZ Stock Holding History

Boenning & Scattergood’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$537K	Hold	3,448	–	–	0.09%	240
2022 Q3	$460K	Hold	3,448	–	–	0.09%	238
2022 Q2	$538K	Hold	3,448	–	–	0.1%	212
2022 Q1	$537K	Hold	3,448	–	–	0.09%	240
2021 Q4	$439K	Hold	3,448	–	–	0.07%	263
2021 Q3	$448K	Hold	3,448	–	–	0.08%	256
2021 Q2	$613K	Hold	3,448	–	–	0.11%	207
2021 Q1	$567K	Hold	3,448	–	–	0.11%	212
2020 Q4	$569K	Sell	3,448 -615	-15%	-$91.6K	0.12%	192
2020 Q3	$579K	Sell	4,063 -85	-2%	-$10.5K	0.14%	166
2020 Q2	$458K	Buy	4,148 +1,148	+38%	+$127K	0.12%	189
2020 Q1	$299K	Buy	+3,000	New	+$388K	0.1%	200

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Boenning & Scattergood's JAZZ Position: Q4 2022 in Review

Boenning & Scattergood held its Jazz Pharmaceuticals (JAZZ) position steady in Q4 2022 at 3,448 shares worth $537K. The position accounts for 0.09% of the portfolio, ranked #240.

Boenning & Scattergood first reported a position in JAZZ in Q1 2020 and has held it in 12 quarters since. The position peaked at $613K in Q2 2021. 485 funds tracked by Wall St. Rank hold JAZZ as of Q4 2022.

Boenning & Scattergood held 3,448 shares of Jazz Pharmaceuticals worth $537K as of Q4 2022.
Boenning & Scattergood left its Jazz Pharmaceuticals share count unchanged in Q4 2022.
Jazz Pharmaceuticals made up 0.09% of Boenning & Scattergood's portfolio in Q4 2022, its #240 holding.
Boenning & Scattergood first reported a position in Jazz Pharmaceuticals in Q1 2020 and has held it in 12 quarters since.
Boenning & Scattergood's Jazz Pharmaceuticals position peaked at $613K in Q2 2021.
485 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2022.

Based on Boenning & Scattergood's 13F filing for Q4 2022, filed 26 Jan 2023.